Lilly partners with OpenAI to develop new antimicrobial drugs
2024-06-25 22:23:40
On Tuesday local time, US pharmaceutical giant Eli Lilly announced that it has partnered with OpenAI to develop new antimicrobial drugs using its generative artificial intelligence (AI). Shares of Eli Lilly rose nearly 2% in US trading. Just this month, the World Health Organization (WHO) released a report saying that antimicrobial resistance (AMR) has become one of the top ten global public health threats. Diogo Rau, chief information and digital officer at Eli Lilly, said: "Our partnership with OpenAI represents a ground-breaking step in the fight against the growing but ignored threat of AMR." Diogo pointed out that generative AI offers a new opportunity to help researchers accelerate the discovery of new antimicrobial drugs and develop specialized technologies in the fight against drug-resistant bacteria. The collaboration between the two companies could help solve major health challenges facing people around the world.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
美国政客可能利用加密货币转移舆论焦点Next article：
OpenAI推迟推出语音助手以解决安全问题
